The involvement of seed genes in multiple biological pathways related to sorafenib and HCC, as well as the common interactions of ADH1A, CYP26A1, VEGF-A, and VEGF-C in signal transduction pathways, should allow future studies on the simultaneous targeting of different signaling pathways or common downstream proteins involved in HCC control and sorafenib response with the aim of personalizing treatment for this still uncurable disease. The gene discussed is CYP26A1; the disease is hepatocellular carcinoma.